Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.

Abstract

We read with great interest the LMS-04 study, reported in The Lancet Oncology by Patricia Pautier and colleagues. 1 Pautier P Italiano A Piperno-Neumann S et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022; 23: 1044-1054 Summary Full Text Full Text PDF PubMed Scopus (4) Google Scholar The longest median progression-free survival documented in the literature to date was with trabectedin–doxorubicin combination therapy in this trial, which was conducted only in the leiomyosarcoma subtype of sarcoma. However, we have some concerns regarding the interpretation of the results of the study. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialDoxorubicin plus trabectedin in first-line therapy was found to significantly increase progression-free survival in patients with metastatic or unresectable leiomyosarcomas compared with doxorubicin alone, despite a higher but manageable toxicity, and could be considered an option for the first-line treatment of metastatic leiomyosarcomas. Full-Text PDF Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcomaWe read with great interest the Article in The Lancet Oncology by Patricia Pautier and colleagues1 reporting the LMS-04 study, which assessed the addition of trabectedin to doxorubicin as first-line therapy in metastatic or relapsed unresectable leiomyosarcoma. In this open-label, randomised, controlled, phase 3 trial, patients with treatment-naive, unresectable, or metastatic leiomyosarcoma were randomly assigned to receive doxorubicin alone once every 3 weeks for up to six cycles or doxorubicin plus trabectedin once every 3 weeks for up to six cycles followed by trabectedin maintenance for up to 17 cycles. Full-Text PDF Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma – Authors' replyWe thank Archana Sasi and colleagues, Osman Sütcüoğlu and colleagues, and Sushant Chib and Ajay Gogia for the interest in our Article.1 Full-Text PDF Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcomaWe read with interest the Article in The Lancet Oncology by Patricia Pautier and colleagues1 reporting their randomised, controlled, phase 3 trial (LMS-04) comparing a combination of doxorubicin and trabectedin versus doxorubicin alone upfront in metastatic or relapsed unresectable leiomyosarcoma. The study reported a progression-free survival benefit in the combination group.1 We applaud the authors for identifying a drug that might be effectively combined with doxorubicin to improve treatment response rates in leiomyosarcoma. Full-Text PDF